Brush border enzyme-cleavable linkers: Evaluation for reducing renal uptake of radiolabeled prostate-specific membrane antigen inhibitors
Radiolabeled, low-molecular-weight prostate-specific membrane antigen (PSMA) inhibitors based on the Glu-ureido pharmacophore show promise for the detection and treatment of castration-resistant prostate cancer; however, high renal retention of activity, related in part to overexpression of PSMA in kidneys can be problematic. The goal of the current study was to investigate the use of brush border enzyme-cleavable linkers as a strategy for reducing kidney activity levels from radiolabeled PSMA inhibitors. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - May 5, 2018 Category: Nuclear Medicine Authors: Ganesan Vaidyanathan, Choong Mo Kang, Darryl McDougald, Il Minn, Mary Brummet, Martin G. Pomper, Michael R. Zalutsky Source Type: research
What about αvβ3 integrins in molecular imaging in oncology?
Non-invasive investigation of integrin expression is an interesting approach in nuclear medicine department. Indeed, integrins are overexpressed in a wide array of diseases, including tumor neoangiogenesis, cardiovascular pathologies, immune dysfunction, etc. Different targets have been identified in order to be detected and quantified for angiogenesis and vascular remodeling, among them VEGF, matrix metalloproteases, and integrins ( αvβ3, but also α5ß1 and αvβ6). Their targeting appears of great interest either for early diagnosis, aggressiveness staging of the disease or for selection of responders to new-targeted ...
Source: Nuclear Medicine and Biology - May 4, 2018 Category: Nuclear Medicine Authors: Frederic Debordeaux, Lucie Chansel-Debordeaux, Jean-Baptiste Pinaquy, Philippe Fernandez, Jurgen Schulz Source Type: research
Gallium-68 labeled Ubiquicidin derived Octapeptide as a potential infection imaging agent
In this study, Ubiquicidin derived octapeptide, UBI (31 –38) conjugated with macrocyclic chelator NOTA was radiolabeled with 68Ga to develop infection imaging agent. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - May 4, 2018 Category: Nuclear Medicine Authors: Jyotsna Bhatt, Archana Mukherjee, Ajit Shinto, K. Kamaleshwaran, Aruna Korde, Mukesh Kumar, Haladhar Dev Sarma, Krishnamohan Repaka, Ashutosh Dash Source Type: research
N-(4-[18F]fluorobenzyl)cholylglycine, a novel tracer for PET of enterohepatic circulation of bile acids: Radiosynthesis and proof-of-concept studies in rats
Enterohepatic circulation (EHC) of conjugated bile acids is an important physiological process crucial for regulation of intracellular concentrations of bile acids and their function as detergents and signal carriers. Only few bile acid-derived imaging agents have been synthesized and hitherto none have been evaluated for studies of EHC. We hypothesized that N-(4-[18F]fluorobenzyl)cholylglycine ([18F]FBCGly), a novel fluorine-18 labeled derivative of endogenous cholylglycine, would be a suitable tracer for PET of the EHC of conjugated bile acids, and we report here a radiosynthesis of [18F]FBCGly and a proof-of-concept stu...
Source: Nuclear Medicine and Biology - May 4, 2018 Category: Nuclear Medicine Authors: Kim Frisch, Damion H.R. Stimson, Taracad Venkatachalam, Gregory K. Pierens, Susanne Keiding, David Reutens, Rajiv Bhalla Source Type: research
Feasibility of myocardial PET imaging using a benzylguanidine analog: meta-(3-[18F]fluoropropyl)benzylguanidine ([18F]mFPBG)
Global and regional sympathetic activity in the heart can be evaluated using [123I]meta-iodobenzylguanidine ([123I]mIBG) imaging. However, [123I]mIBG is associated with low image spatial resolution and sensitivity in cardiac imaging. We investigated the capability of an F-18-labeled mIBG derivative, meta-(3-[18F]fluoropropyl)benzylguanidine ([18F]mFPBG), for identifying ischemic and viable myocardium in a rat model of myocardial infarction. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - May 3, 2018 Category: Nuclear Medicine Authors: Sang-Keun Woo, Byung Seok Moon, Bom Sahn Kim, Min Hwan Kim, Yong Jin Lee, Jae Ho Jung, Kyo Chul Lee, Youngho Seo, Wook Kim, Sang Moo Lim, Byung Chul Lee, Sang Eun Kim Source Type: research
Editorial Board
(Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - May 1, 2018 Category: Nuclear Medicine Source Type: research
Table of Contents
(Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - May 1, 2018 Category: Nuclear Medicine Source Type: research
Corrigendum to ‘212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models’ [Nucl Med Biol 58 (2018) 67–73]
The authors regret that a funding source was not acknowledged in the original paper. The correct Financial Support statement can be seen below. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - April 25, 2018 Category: Nuclear Medicine Authors: Benjamin B. Kasten, Abhishek Gangrade, Harrison Kim, Jinda Fan, Soldano Ferrone, Cristina R. Ferrone, Kurt R. Zinn, Donald J. Buchsbaum Tags: Corrigendum Source Type: research
[18F]-GE-179 positron emission tomography (PET) tracer for N-methyl-d-aspartate receptors: One-pot synthesis and preliminary micro-PET study in a rat model of MCAO
The objective of this study was to synthesize an N-methyl-d-aspartate receptor (NMDAR) radiotracer [18F]-GE-179 in one-pot and evaluate its in vivo binding for NMDAR activation after brain ischemia reperfusion injury. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - April 24, 2018 Category: Nuclear Medicine Authors: Weiyan Zhou, Weiqi Bao, Donglang Jiang, Yanyan Kong, Fengchun Hua, Xiuhong Lu, Yihui Guan Source Type: research
Microscale radiosynthesis, preclinical imaging and dosimetry study of [18F]AMBF3-TATE: a potential PET tracer for clinical imaging of somatostatin receptors
Peptides labeled with positron-emitting isotopes are emerging as a versatile class of compounds for the development of highly specific, targeted imaging agents for diagnostic imaging via positron-emission tomography (PET) and for precision medicine via theranostic applications. Despite the success of peptides labeled with gallium-68 (for imaging) or lutetium-177 (for therapy) in the clinical management of patients with neuroendocrine tumors or prostate cancer, there are significant advantages of using fluorine-18 for imaging. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - April 20, 2018 Category: Nuclear Medicine Authors: Ksenia Lisova, Maxim Sergeev, Susan Evans-Axelsson, Andreea D. Stuparu, Seval Beykan, Jeffrey Collins, Jason Jones, Michael Lassmann, Ken Herrmann, David Perrin, Jason T. Lee, Roger Slavik, Michael van Dam Source Type: research
Development of a novel radiobromine-labeled sigma-1 receptor imaging probe
Sigma-1 receptor is a target for tumor imaging. In a previous study, we synthesized a vesamicol analog, (+)-2-[4-(4-bromophenyl)piperidino]cyclohexanol [(+)-pBrV], with a high affinity for sigma-1 receptor, and synthesized radiobrominated (+)-pBrV. This radiobrominated (+)-pBrV showed high tumor uptake in tumor-bearing mice; however, radioactivity accumulation in normal tissues, such as the liver, was high. We assumed that the accumulation of (+)-pBrV in the non-target tissues was partially derived from its high lipophilicity; therefore, we synthesized and evaluated (+)-4-[1-(2-hydroxycyclohexyl)piperidine-4-yl]-2-bromophe...
Source: Nuclear Medicine and Biology - April 6, 2018 Category: Nuclear Medicine Authors: Kazuma Ogawa, Ryohei Masuda, Yoshiaki Mizuno, Akira Makino, Takashi Kozaka, Yoji Kitamura, Yasushi Kiyono, Kazuhiro Shiba, Akira Odani Source Type: research
Editorial Board
(Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - April 1, 2018 Category: Nuclear Medicine Source Type: research
